Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial

Chenlu Yang, Qing Li, Yu Wu

Blood (2025) 146 (Supplement 1): 5625.

https://doi.org/10.1182/blood-2025-5625

Published: 2025

Journal Articles

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

Kai Shen, Chenlu Yang, Jinrong Yang, He Li, Jie Wang, Jiazhuo Liu, Yun Tang, Chuan He, Bing Xiang, Ting Niu

Blood (2025) 146 (Supplement 1): 7433.

https://doi.org/10.1182/blood-2025-7433

Published: 2025

Journal Articles

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

Kai Shen, Chenlu Yang, Jinrong Yang, He Li, Jie Wang, Jiazhuo Liu, Yun Tang, Chuan He, Bing Xiang, Ting Niu

Blood (2025) 146 (Supplement 1): 7422.

https://doi.org/10.1182/blood-2025-7422

Published: 2025

Journal Articles

Real-world outcomes and a novel prognostic assessment model for high-risk acute promyelocytic leukemia receiving all-trans retinoid acid and arsenic trioxide dual induction based on lasso-cox regression

Kai Shen, Chenlu Yang, Hongbing Ma

Blood (2025) 146 (Supplement 1): 1603.

https://doi.org/10.1182/blood-2025-1603

Published: 2025

Journal Articles

Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study

Jie Wang, He Li, Chenlu Yang, Di Wu, Xingli Zou, Tao Yang, Liangliang Ma, Fang Xu, Jie Wang, Minggang Su, Sha Zhao, Lin Ji, Yao Liu, Pengcheng He, Ting Niu

Blood (2024) 144 (Supplement 1): 4488.

https://doi.org/10.1182/blood-2024-193927

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

Real-world outcomes and a novel prognostic assessment model for high-risk acute promyelocytic leukemia receiving all-trans retinoid acid and arsenic trioxide dual induction based on lasso-cox regression

Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

Real-world outcomes and a novel prognostic assessment model for high-risk acute promyelocytic leukemia receiving all-trans retinoid acid and arsenic trioxide dual induction based on lasso-cox regression

Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only